NEW YORK November 7, 2019 – Kadmon Holdings, Inc. (NYSE: KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) in the People’s Republic of China.